Fig. 3: Humoral responses from LASV Togo-infected AGMs treated with 4′-FIU.
From: Oral 4′-fluorouridine rescues nonhuman primates from advanced Lassa fever
a, LASV GPC-specific IgG binding titres from AGM as measured by ELISA. b–d, Antibody neutralization activity from 4′-FIU-treated AGMs at challenge (b), at 14 DPI (c) and 35 DPI (d), as measured by PRNT. Calculated neutralization values that were negative are plotted as zero. In c, data from the untreated positive control AGM are from the terminal time point (11 DPI) for that monkey. Horizontal dotted lines in b–d indicate 50% neutralization compared with the virus control plate. Data shown are the mean of two replicate assays on the same biological sample. For the untreated positive control cohort, n = 6 monkeys; for the 4′-FIU-treated cohort, n = 5 monkeys. In a,b, the bars represent the mean antibody binding titre ± s.d.
